Page 4 - Merck Press News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofThomas powlesAmerican society of clinical oncologyHead of development unit oncologyMerck pressEuropean commissionDrug administrationQueen mary university of londonSolid tumor research at barts cancer instituteAmerican cancer societyBarts cancer centreUnited kingdom basedClinical oncologyGenitourinary cancers symposium

Merck: Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance

United statesUnited kingdomCity ofNoelle piscitelliThomas powlesAmerican society of clinical oncologyHead of development unit oncologyMerck pressEuropean commissionDrug administrationQueen mary university of londonSolid tumor research at barts cancer instituteAmerican cancer societyBarts cancer centreUnited kingdom basedClinical oncology

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMerck pressHead of global developmentChord therapeuticsDanny bar zoharGlobal developmentOmega fundsImmunology merckAll merck press releases

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

United statesUnited kingdomBrauti fritzenMerck pressHead of global developmentMyasthenia gravisNeuromyelitis optica spectrum disorderMultiple sclerosisChord therapeuticsDanny bar zoharGlobal developmentOmega fundsMerck press releasesMedia contactScience and technologyChord therapeutics

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO®

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releasesMedia contactRal met inhibitor